Skip to main content
Premium Trial:

Request an Annual Quote

Waters' Q1 Revenues Jump 10 Percent

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Waters today reported a 10 percent increase in its first-quarter 2010 revenues, citing demand for new products and improving end markets.

The Milford, Mass.-based life science research and environmental testing products firm brought in total revenues of $367.7 million for the three-month period ended April 3, 2010, compared to $333.1 million for the first quarter of 2009. Its Q1 2010 revenues beat analysts' consensus estimate of $359.2 million.

Excluding a foreign currency translation benefit of 4 percent, Waters' sales were up 6 percent year over year.

"Strong demand for our new products and improving end-markets contributed to our sales growth in the first quarter," Waters Chairman, President, and CEO Douglas Berthiaume, said in a statement. "Shipments of our new instrument systems, including the Synapt G-2 and Acquity UPLC H-Class, ramped up nicely in the quarter while our TA Instruments sales returned to growth based on strong product positions and improving demand from industrial chemical customers."

Waters posted a profit of $75.5 million, or $.79 per share, up from $73.3 million, or $.75 per share, for the first quarter of 2009. The firm beat analysts' consensus estimate for EPS of $.78.

Its R&D spending for the quarter increased 10 percent to $20.1 million from $18.3 million, while its SG&A spending rose 7 percent to $106.7 million from $99.2 million.

Waters finished the quarter with $692.2 million in cash, cash equivalents, and short-term investments.

During a conference call this morning, Berthiaume said that the firm has lowered its expectations for stimulus-related revenues to a range of $10 million to $15 million from its previous expectations of $20 million to $30 million.

For full-year 2010, Waters anticipates sales to grow between 5 percent and 7 percent on a currency-neutral basis, to between $1.575 billion and $1.605 billion.

In Tuesday trade on the New York Stock Exchange, shares of Waters closed up under 1 percent at $70.33. Its shares traded as high as $72.58 during the day.

The Scan

More Boosters for US

Following US Food and Drug Administration authorization, the Centers for Disease Control and Prevention has endorsed booster doses of the Moderna and Johnson & Johnson SARS-CoV-2 vaccines, the Washington Post writes.

From a Pig

A genetically modified pig kidney was transplanted into a human without triggering an immune response, Reuters reports.

For Privacy's Sake

Wired reports that more US states are passing genetic privacy laws.

Science Paper on How Poaching Drove Evolution in African Elephants

In Science this week: poaching has led to the rapid evolution of tuskless African elephants.